0.353  -0.021 (-5.49%)		07-26 16:00
Open: 0.3767 High: 0.4 Volume: 292,550		Pre. Close: 0.3735 Low: 0.352 Market Cap: 4(M)

Short term
Mid term
Targets	6-month :	0.66	1-year :	0.87
Resists	First :	0.57	Second :	0.75
Pivot price	0.38
Supports	First :	0.28	Second :	0.23
MAs	MA(5) :	0.35	MA(20) :	0.37
	MA(100) :	0.78	MA(250) :	4.93
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	13.6	D(3) :	13.7
RSI	RSI(14): 40.7
52-week	High :	15.6	Low :	0.28

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ CING ] has closed above bottom band by 38.4%. Bollinger Bands are 6.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	0.4 - 0.4	0.4 - 0.4
Low:	0.35 - 0.35	0.35 - 0.35
Close:	0.35 - 0.35	0.35 - 0.36

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Thu, 18 Jul 2024
Short Interest in Cingulate Inc. (NASDAQ:CING) Declines By 5.8% - American Banking and Market News

Tue, 21 May 2024
FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD - Yahoo Finance

Mon, 01 Apr 2024
Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update - GlobeNewswire

Wed, 28 Feb 2024
Cingulate regains compliance with Nasdaq, maintaining key capital source - Kansas City Business Journal

Tue, 13 Feb 2024
Cingulate Inc Bolsters Board, Targets Nasdaq Compliance - TipRanks

Thu, 08 Feb 2024
Pharma company Cingulate raises $7.5M from public offering - Kansas City Business Journal

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	9 (M)
Held by Insiders	5.97e+006 (%)
Held by Institutions	17.3 (%)
Shares Short	279 (K)
Shares Short P.Month	0 (K)

EPS	-2.121e+007
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-215.9 %
Return on Equity (ttm)	-1 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-3.41
Qtrly Earnings Growth	-19.6 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-20 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	-0.61

Dividend	0
Forward Dividend	192450
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.